R
Rüdiger Göke
Researcher at University of Marburg
Publications - 96
Citations - 7289
Rüdiger Göke is an academic researcher from University of Marburg. The author has contributed to research in topics: Receptor & Insulin. The author has an hindex of 39, co-authored 95 publications receiving 7056 citations. Previous affiliations of Rüdiger Göke include University of Göttingen & University of Michigan.
Papers
More filters
Journal ArticleDOI
Islet amyloid polypeptide (IAPP;amylin) influences the endocrine but not the exocrine rat pancreas.
TL;DR: The data suggest amylin, a secretory product of pancreatic B-cells, as a peptide with approximately strong paracrine effects within the Langerhans islet might be involved in the regulation of glucose homeostasis.
Journal ArticleDOI
Signal transduction of the GLP-1-receptor cloned from a human insulinoma.
TL;DR: The understanding of GLP‐1 receptor regulation and signal transduction will aid in the discovery of compounds that act as agonists of the GLP•1 receptor for potential use in the treatment of diabetes and will facilitate the understanding of its expression under normal and pathophysiological conditions.
Journal ArticleDOI
Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.
TL;DR: This in vitro studies aimed to characterize the pattern and the kinetics of endoproteolysis of the insulinotropic hormone glucagon-like peptide-1 (GLP-1) and related peptides by native ectopeptidases and found that exendin-4 is several orders of magnitude more stable than GLP- 1 and Ser-8-GLp-1 is especially noteworthy given this peptide's widely reported insulinotropic potency.
Journal ArticleDOI
Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary
TL;DR: Using quantitative in vitro autoradiography, a high density of specific binding sites for GLP-1 was characterized on sections of the posterior pituitary lobe of the rat, revealing high and low affinity binding sites.
Journal ArticleDOI
Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Patricia Grabowski,Sonja Griss,Christian N. Arnold,Dieter Hörsch,Rüdiger Göke,Rudolf Arnold,Bernhard Heine,Harald Stein,Martin Zeitz,Hans Scherübl +9 more
TL;DR: Nuclear survivin expression appears to be upregulated during progression of gastroenteropancreatic neuroendocrine tumors, which identifies subgroups in metastatic disease with good (survivin–) or with less favorable prognosis (Survivin+).